Urovant Sciences Ltd

+0.01 (+0.06%)
Mergers / Acquisitions

Sumitovant Biopharma, Urovant Sciences Report Sumitovant's Acquisition Of Remaining Stake In Urovant

Published: 11/12/2020 22:16 GMT
Urovant Sciences Ltd (UROV) - Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant.
Sumitovant Biopharma - Sumitovant Biopharma to Acquire All Outstanding Shares of Urovant It Does Not Already Own.
Sumitovant Biopharma - Agreement Unanimously Recommended by Special Committee of Urovant Independent Directors.
Sumitovant Biopharma - Acquisition Consideration Represents an Equity Value for Urovant of $584 Million.
Sumitovant Biopharma - Upon Closing, Urovant Will Become Unit of Sumitovant, Urovant's Common Stock Will Cease Trading on Nasdaq Stock Market.
Sumitovant Biopharma - Entered Merger Agreement for Co to Buy Outstanding Shares of Urovant Common Stock Not Already Owned by Co at $16.25/share in Cash.